Small-molecule fluorescence-based probes for aging diagnosis

Abstract

Aging is a time-dependent decline in physiological function that affects most organisms and is the major risk factor for many non-communicable diseases. The early diagnosis of aging is critical for the treatment of aging and aging-related diseases. In recent years, extensive efforts have attempted to accurately diagnose aging. To date, multiple types of fluorescent probes for various age-related biomarkers have been developed, with the aims of achieving rapid, precise diagnosis of the aging process and evaluating the efficacy of anti-aging drugs. This review summarizes recent research progress in small-molecule fluorescence-based probes for aging diagnosis, and further discusses the challenges and opportunities in this field.

SIRT6 mediates multidimensional modulation to maintain organism homeostasis

“…This makes it imperative to develop antiaging drugs and strategies that can extend healthspan (Partridge et al, 2020). Due to the limitation of aging models and evaluation criteria of antiaging efficacy, the current research on antiaging drugs is still in a slow stage (Shi et al, 2022). Overexpression and activation of SIRT6, by contrast, enhance multiple pathways of organism homeostasis owing to its upstream regulatory role.…”

Dual-Parameter Recognition-Directed Design of the Activatable Fluorescence Probe for Precise Imaging of Cellular Senescence

“…Fluorescence imaging, owing to many merits such as high sensitivity, nanometer spatiotemporal resolution, dynamic feedback, and convenience, has become an indispensable technique for real-time analysis and dynamic visualization of important biological events in complex living systems at the cellular and molecular levels. − Indeed, considerable efforts have been devoted to constructing fluorescent probes by virtue of the unique biochemical features during cellular senescence, which are routinely designed by detecting the expression of senescence-associated beta-galactosidase (SA-β-gal), − currently the gold-standard biomarker of senescence. Although tracking senescence has been achieved in several cellular and animal models, the reliability of these probes is often concerned, because the overexpression of SA-β-gal has also been identified in some non-senescent cells. − To overcome this limitation, recent attempts have been made to develop probes by targeting other potential features including lipofuscin, sialidase, α-fucosidase, and ions .…”

A senolysis-based theragnostic prodrug strategy towards chronic renal failure

“…Up to now, dozens of b-galactosidase (b-gal) activable uorescent probes have been constructed to identify SNCs. [29][30][31][32][33][34][35][36][37] The recent years have also witnessed a rapid development of b-gal activable prodrugs as senolytics for the treatment of age-related diseases. [38][39][40][41][42] However, to the best of our knowledge, theragnostic prodrugs capable of senolysis and identifying SNCs are rarely reported, and there is no research on the construction of SA-b-gal activable prodrugs as senolytics for the treatment of CRF.…”